State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia and WHO Collaborating Centre for Prevention and Care Management of Echinococcosis, Urumqi, China.
WHO Collaborating Centre for Prevention and Treatment of Human Echinococcosis and French National Centre for Echinococcosis, University Bourgogne Franche-Comte and University Hospital, Besançon, France.
Clin Microbiol Rev. 2019 Feb 13;32(2). doi: 10.1128/CMR.00075-18. Print 2019 Mar 20.
Echinococcosis is a zoonosis caused by cestodes of the genus (family Taeniidae). This serious and near-cosmopolitan disease continues to be a significant public health issue, with western China being the area of highest endemicity for both the cystic (CE) and alveolar (AE) forms of echinococcosis. Considerable advances have been made in the 21st century on the genetics, genomics, and molecular epidemiology of the causative parasites, on diagnostic tools, and on treatment techniques and control strategies, including the development and deployment of vaccines. In terms of surgery, new procedures have superseded traditional techniques, and total cystectomy in CE, resection with autotransplantation in AE, and percutaneous and perendoscopic procedures in both diseases have improved treatment efficacy and the quality of life of patients. In this review, we summarize recent progress on the biology, epidemiology, diagnosis, management, control, and prevention of CE and AE. Currently there is no alternative drug to albendazole to treat echinococcosis, and new compounds are required urgently. Recently acquired genomic and proteomic information can provide a platform for improving diagnosis and for finding new drug and vaccine targets, with direct impact in the future on the control of echinococcosis, which continues to be a global challenge.
包虫病是一种由带科(带科)绦虫属引起的人畜共患病。这种严重的、近乎世界性的疾病仍然是一个重大的公共卫生问题,中国西部是囊型(CE)和泡型(AE)包虫病高发区。在寄生虫的遗传学、基因组学和分子流行病学、诊断工具以及治疗技术和控制策略方面,包括疫苗的开发和应用,都取得了相当大的进展。在手术方面,新的程序已经取代了传统的技术,CE 的全囊切除术、AE 的切除和自体移植术、以及这两种疾病的经皮和经内镜手术,都提高了治疗效果和患者的生活质量。在这篇综述中,我们总结了 CE 和 AE 的生物学、流行病学、诊断、管理、控制和预防方面的最新进展。目前尚无替代阿苯达唑治疗包虫病的药物,急需新的化合物。最近获得的基因组和蛋白质组信息可以为改善诊断和寻找新的药物和疫苗靶点提供一个平台,这将对包虫病的未来控制产生直接影响,包虫病仍然是一个全球性的挑战。